BioXcel Therapeutics, Inc.
TREATMENT OF SARCOMA USING IMMUNOMODULATION

Abstract:

The present disclosure provides a method for treating a subject afflicted with sarcoma selected from soft tissue sarcoma (such as liposarcoma, myxoid sarcoma) and osteosarcoma by administering Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab, wherein Talabostat or a pharmaceutically acceptable salt thereof is administered at a dose of about 0.3 mg twice daily on one or more days of a treatment cycle.